User:Eliška Koutná/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 29: | Line 29: | ||
=== Creutzfeld-Jacob disease === | === Creutzfeld-Jacob disease === | ||
Creutzfeld-Jacob disease (CJD) is the most common human prion disease. It occurs in three distinct forms, based on the source of the disease: sporadic, acquired and inherited <ref>DOI 10.1016/bs.pmbts.2017.06.010</ref>. Sporadic form of CJD is denoted as sCJD and it predominantly affects middle aged and elderly. Its classical clinical symptoms are rapid cognitive decline, dementia, cerebellar ataxia and myoclonus terminating in an akinetic mute state <ref>DOI 10.12688/f1000research.12681.1</ref>. Due to a very rapid progress of the disease, mean survival of patients is merely six months and more than 90 % die within a year from onset of the first symptoms <ref>DOI 10.1212/01.WNL.0000160117.56690.B2</ref>. There are certain speculations about the cause of sCJD, e.g. stochastic protein folding or a somatic mutation in PRNP gene, but the true reasons remain unrevealed <ref>DOI 10.1016/bs.pmbts.2017.06.010</ref>. | Creutzfeld-Jacob disease (CJD) is the most common human prion disease. It occurs in three distinct forms, based on the source of the disease: sporadic, acquired and inherited <ref>DOI 10.1016/bs.pmbts.2017.06.010</ref>. Sporadic form of CJD is denoted as sCJD and it predominantly affects middle aged and elderly. Its classical clinical symptoms are rapid cognitive decline, dementia, cerebellar ataxia and myoclonus terminating in an akinetic mute state <ref>DOI 10.12688/f1000research.12681.1</ref>. Due to a very rapid progress of the disease, mean survival of patients is merely six months and more than 90 % die within a year from onset of the first symptoms <ref>DOI 10.1212/01.WNL.0000160117.56690.B2</ref>. There are certain speculations about the cause of sCJD, e.g. stochastic protein folding or a somatic mutation in PRNP gene, but the true reasons remain unrevealed <ref>DOI 10.1016/bs.pmbts.2017.06.010</ref>. | ||
| - | Acquired forms of CJD are caused by infection from exogenous source and consist of variant CJD (vCJD) and iatrogenic CJD (iCJD). Latter is caused by accidental transmission of the disease through medical and surgical procedures, mainly by cadaveric-derived human dura mater grafts (e.g. in cases of corneal transplantation (Duffy P, 1974; Maddox RA, 2008)) or by treatment with human growth hormone (hGH) originating from sCJD affected pituitary glands (Peden AH, 2007). Additionally, few cases caused by treatment with infected human gonadotropin were also described (Cochius JI, 1992). Symptoms of iCJD are generally identical with those of sCJD. However, cases caused by infected hGH are more specific, i.e. progressive cerebellar ataxia and lower limb dysaesthesia with other features, including cognitive impairment (Rudge P et al., 2015). | ||
| - | The vCJD form was described for the first time during the BSE epidemic in the United Kingdom in 1996 and was termed as the “new variant CJD” (Will RG, 1996). It is primarily caused by ingestion of food with infectious contamination originating from BSE affected cattle (Ward HJ et al., 2006). Nonetheless, infection can also arise from transfusion by an infected blood (Urwin PJ et al., 2016) or a blood product, i.e. factor VIII important in the pathway of the blood coagulation (Peden A et al., 2010). The BSE epidemic is the main reason for which the vCJD still occurs with highest incidence in the UK and France. Since the 1996 till 25.04.2017, total count of 231 definite or probable cases of vCJD was reported (Knight R, 2017). Symptoms of vCJD are again mostly identical or very similar to those of other CJD forms, including painful sensory symptoms and involuntary movements (Heath CA et al., 2010). In compare with sCJD, mean survival of patients from the onset symptoms is significantly longer, approximately 14 months from the onset symptoms (Heath CA et al., 2011). | ||
| - | Acquired forms of CJD are caused by infection from exogenous source and consist of variant CJD (vCJD) and iatrogenic CJD (iCJD). Latter is caused by accidental transmission of the disease through medical and surgical procedures, mainly by cadaveric-derived human dura mater grafts | + | Acquired forms of CJD are caused by infection from exogenous source and consist of variant CJD (vCJD) and iatrogenic CJD (iCJD). Latter is caused by accidental transmission of the disease through medical and surgical procedures, mainly by cadaveric-derived human dura mater grafts (e.g. in cases of corneal transplantation <ref>DOI 10.1056/NEJM197403212901220</ref> <ref>DOI 10.1097/ICO.0b013e31816a628d</ref>) or by treatment with human growth hormone (hGH) originating from sCJD affected pituitary glands <ref>DOI 10.1099/vir.0.81913-0</ref>. Additionally, few cases caused by treatment with infected human gonadotropin were also described <ref>PMID 1469410</ref>. Symptoms of iCJD are generally identical with those of sCJD. However, cases caused by infected hGH are more specific, i.e. progressive cerebellar ataxia and lower limb dysaesthesia with other features, including cognitive impairment <ref>DOI 10.1093/brain/awv235</ref>. |
| - | The vCJD form is caused by | + | |
| + | The vCJD form was described for the first time during the BSE epidemic in the United Kingdom in 1996 and was termed as the “new variant CJD” <ref>PMID 8598754</ref>. It is primarily caused by ingestion of food with infectious contamination originating from BSE affected cattle (Ward HJ et al., 2006). Nonetheless, infection can also arise from transfusion by an infected blood (Urwin PJ et al., 2016) or a blood product, i.e. factor VIII important in the pathway of the blood coagulation (Peden A et al., 2010). The BSE epidemic is the main reason for which the vCJD still occurs with highest incidence in the UK and France. Since the 1996 till 25.04.2017, total count of 231 definite or probable cases of vCJD was reported (Knight R, 2017). Symptoms of vCJD are again mostly identical or very similar to those of other CJD forms, including painful sensory symptoms and involuntary movements (Heath CA et al., 2010). In compare with sCJD, mean survival of patients from the onset symptoms is significantly longer, approximately 14 months from the onset symptoms (Heath CA et al., 2011). | ||
== Diagnosis and treatment == | == Diagnosis and treatment == | ||
Revision as of 23:01, 28 April 2019
Prions
| |||||||||||
References
- ↑ Imran M, Mahmood S. An overview of animal prion diseases. Virol J. 2011 Nov 1;8:493. doi: 10.1186/1743-422X-8-493. PMID:22044871 doi:http://dx.doi.org/10.1186/1743-422X-8-493
- ↑ Prusiner SB. Prion diseases and the BSE crisis. Science. 1997 Oct 10;278(5336):245-51. doi: 10.1126/science.278.5336.245. PMID:9323196 doi:http://dx.doi.org/10.1126/science.278.5336.245
- ↑ 3.0 3.1 3.2 3.3 Sigurdson CJ, Bartz JC, Glatzel M. Cellular and Molecular Mechanisms of Prion Disease. Annu Rev Pathol. 2019 Jan 24;14:497-516. doi:, 10.1146/annurev-pathmechdis-012418-013109. Epub 2018 Oct 24. PMID:30355150 doi:http://dx.doi.org/10.1146/annurev-pathmechdis-012418-013109
- ↑ Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121-321). Nature. 1996 Jul 11;382(6587):180-2. PMID:8700211 doi:10.1038/382180a0
- ↑ doi: https://dx.doi.org/10.1073/pnas.97.1.145
- ↑ Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science. 2005 Jun 3;308(5727):1435-9. doi: 10.1126/science.1110837. PMID:15933194 doi:http://dx.doi.org/10.1126/science.1110837
- ↑ 7.0 7.1 7.2 7.3 Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, et al.. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10962-6. PMID:7902575
- ↑ Wille H, Requena JR. The Structure of PrP(Sc) Prions. Pathogens. 2018 Feb 7;7(1). pii: pathogens7010020. doi: 10.3390/pathogens7010020. PMID:29414853 doi:http://dx.doi.org/10.3390/pathogens7010020
- ↑ 9.0 9.1 9.2 9.3 Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem. 1998;67:793-819. doi: 10.1146/annurev.biochem.67.1.793. PMID:9759504 doi:http://dx.doi.org/10.1146/annurev.biochem.67.1.793
- ↑ 10.2210/pdb4E1I/pdb
- ↑ 11.0 11.1 11.2 doi: https://dx.doi.org/10.1126/science.7909169
- ↑ Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature. 2003 Oct 16;425(6959):717-20. doi: 10.1038/nature01979. PMID:14562104 doi:http://dx.doi.org/10.1038/nature01979
- ↑ 13.0 13.1 Khanam H, Ali A, Asif M, Shamsuzzaman. Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review. Eur J Med Chem. 2016 Nov 29;124:1121-1141. doi: 10.1016/j.ejmech.2016.08.006., Epub 2016 Aug 6. PMID:27597727 doi:http://dx.doi.org/10.1016/j.ejmech.2016.08.006
- ↑ Aucouturier P, Carp RI, Carnaud C, Wisniewski T. Prion diseases and the immune system. Clin Immunol. 2000 Aug;96(2):79-85. doi: 10.1006/clim.2000.4875. PMID:10900153 doi:http://dx.doi.org/10.1006/clim.2000.4875
- ↑ Casalone C, Hope J. Atypical and classic bovine spongiform encephalopathy. Handb Clin Neurol. 2018;153:121-134. doi: 10.1016/B978-0-444-63945-5.00007-6. PMID:29887132 doi:http://dx.doi.org/10.1016/B978-0-444-63945-5.00007-6
- ↑ Konold T, Bone G, Ryder S, Hawkins SA, Courtin F, Berthelin-Baker C. Clinical findings in 78 suspected cases of bovine spongiform encephalopathy in Great Britain. Vet Rec. 2004 Nov 20;155(21):659-66. PMID:15581140
- ↑ doi: https://dx.doi.org/10.1111/j.1749-6632.1994.tb38911.x
- ↑ Espinosa JC, Morales M, Castilla J, Rogers M, Torres JM. Progression of prion infectivity in asymptomatic cattle after oral bovine spongiform encephalopathy challenge. J Gen Virol. 2007 Apr;88(Pt 4):1379-83. doi: 10.1099/vir.0.82647-0. PMID:17374785 doi:http://dx.doi.org/10.1099/vir.0.82647-0
- ↑ Knight R. Infectious and Sporadic Prion Diseases. Prog Mol Biol Transl Sci. 2017;150:293-318. doi: 10.1016/bs.pmbts.2017.06.010., Epub 2017 Aug 14. PMID:28838665 doi:http://dx.doi.org/10.1016/bs.pmbts.2017.06.010
- ↑ Mackenzie G, Will R. Creutzfeldt-Jakob disease: recent developments. F1000Res. 2017 Nov 27;6:2053. doi: 10.12688/f1000research.12681.1. eCollection, 2017. PMID:29225787 doi:http://dx.doi.org/10.12688/f1000research.12681.1
- ↑ Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Klug GM, Sutcliffe T, Giulivi A, Alperovitch A, Delasnerie-Laupretre N, Brandel JP, Poser S, Kretzschmar H, Rietveld I, Mitrova E, Cuesta Jde P, Martinez-Martin P, Glatzel M, Aguzzi A, Knight R, Ward H, Pocchiari M, van Duijn CM, Will RG, Zerr I. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005 May 10;64(9):1586-91. doi: 10.1212/01.WNL.0000160117.56690.B2. PMID:15883321 doi:http://dx.doi.org/10.1212/01.WNL.0000160117.56690.B2
- ↑ Knight R. Infectious and Sporadic Prion Diseases. Prog Mol Biol Transl Sci. 2017;150:293-318. doi: 10.1016/bs.pmbts.2017.06.010., Epub 2017 Aug 14. PMID:28838665 doi:http://dx.doi.org/10.1016/bs.pmbts.2017.06.010
- ↑ Neumann DA. Letter: Hepatitis with hindsight. N Engl J Med. 1974 Mar 21;290(12):692. doi: 10.1056/NEJM197403212901220. PMID:4591848 doi:http://dx.doi.org/10.1056/NEJM197403212901220
- ↑ Maddox RA, Belay ED, Curns AT, Zou WQ, Nowicki S, Lembach RG, Geschwind MD, Haman A, Shinozaki N, Nakamura Y, Borer MJ, Schonberger LB. Creutzfeldt-Jakob disease in recipients of corneal transplants. Cornea. 2008 Aug;27(7):851-4. doi: 10.1097/ICO.0b013e31816a628d. PMID:18650677 doi:http://dx.doi.org/10.1097/ICO.0b013e31816a628d
- ↑ Peden AH, Ritchie DL, Uddin HP, Dean AF, Schiller KA, Head MW, Ironside JW. Abnormal prion protein in the pituitary in sporadic and variant Creutzfeldt-Jakob disease. J Gen Virol. 2007 Mar;88(Pt 3):1068-72. doi: 10.1099/vir.0.81913-0. PMID:17325383 doi:http://dx.doi.org/10.1099/vir.0.81913-0
- ↑ Cochius JI, Hyman N, Esiri MM. Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin: a second case. J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1094-5. PMID:1469410
- ↑ Rudge P, Jaunmuktane Z, Adlard P, Bjurstrom N, Caine D, Lowe J, Norsworthy P, Hummerich H, Druyeh R, Wadsworth JD, Brandner S, Hyare H, Mead S, Collinge J. Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain. 2015 Nov;138(Pt 11):3386-99. doi: 10.1093/brain/awv235. Epub 2015 Aug 11. PMID:26268531 doi:http://dx.doi.org/10.1093/brain/awv235
- ↑ Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996 Apr 6;347(9006):921-5. PMID:8598754
